Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 4 evaluation of Yi-Qi-Tong-Luo granule for qi deficiency and blood stasis syndrome
ChiCTR1800019585Phase 4Recruiting
- Sponsor
- Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine Ethics Committee
- Start
- May 2018
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in ischemic stroke, coronary arteriosclerosis, diabetic polyneuropathy (DPN) and 1 more comparing Conventional treatment + Yi-Qi-Tong-Luo granule placebo with Conventional treatment + Yi-Qi-Tong-Luo granule (2 arms). Primary endpoint: Evaluation scale of qi deficiency and blood stasis syndrome. Started May 2018; status: recruiting.
02
Drugs
Yiqitongluo granule
03
Conditions
ischemic strokecoronary arteriosclerosisdiabetic polyneuropathy (DPN)Qi deficiency and blood stasis syndrome (QDBS)
Beyond the preview
Go deeper on ChiCTR1800019585.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800019585.